Shaping Clinical Policy for Salvage Radiotherapy After Radical Prostatectomy in Prostate Cancer: Bridging the Gap...

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Salvage radiotherapy (sRT) can yield outcomes similar to adjuvant radiotherapy (aRT) when initiated promptly upon biochemical recurrence after radical prostatectomy (RP).
• The RADICALS-RT trial provided evidence supporting early sRT, establishing observation with early sRT as a new standard of care.
• This study examines the real-world influence of the RADICALS-RT trial on the timing of sRT in prostate cancer management.

Purpose of the Study:

• To assess the impact of the RADICALS-RT trial findings on clinical practice regarding the timing of salvage radiotherapy (sRT) for prostate cancer patients treated with radical prostatectomy (RP).

Main Methods:

• Retrospective analysis of data from 297 patients who received sRT post-RP.
• Patients were categorized into three groups based on the timing of RADICALS-RT presentation and subsequent institutional policy changes (October 2021).
• Comparison of prostate-specific antigen (PSA) levels at the time of sRT across the defined patient groups.

Main Results:

• Median PSA levels at sRT initiation were 0.33 ng/mL (Group 1), 0.27 ng/mL (Group 2), and 0.2 ng/mL (Group 3).
• Fewer than one-third of patients in Groups 1 and 2 had a postoperative PSA ≤ 0.2 ng/mL at sRT.
• Group 3 demonstrated statistically significant differences in median PSA at sRT compared to Groups 1 and 2, indicating earlier intervention.

Conclusions:

• The RADICALS-RT trial's influence on clinical practice was most pronounced after its findings were integrated with local institutional data and evidence.
• This suggests that while landmark trials provide crucial evidence, their translation into practice is often facilitated by site-specific validation and policy adaptation.